Compare MTA & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTA | CTMX |
|---|---|---|
| Founded | 1983 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 685.0M | 596.2M |
| IPO Year | N/A | 2015 |
| Metric | MTA | CTMX |
|---|---|---|
| Price | $8.10 | $4.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $7.50 | $6.50 |
| AVG Volume (30 Days) | 531.7K | ★ 2.8M |
| Earning Date | 02-17-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.22 |
| EPS | N/A | ★ 0.24 |
| Revenue | $10,546,000.00 | ★ $113,631,000.00 |
| Revenue This Year | $127.20 | N/A |
| Revenue Next Year | $75.15 | N/A |
| P/E Ratio | ★ N/A | $17.20 |
| Revenue Growth | ★ 108.91 | N/A |
| 52 Week Low | $2.52 | $0.40 |
| 52 Week High | $8.63 | $4.66 |
| Indicator | MTA | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 57.81 | 51.55 |
| Support Level | $7.49 | $3.98 |
| Resistance Level | $8.30 | $4.66 |
| Average True Range (ATR) | 0.33 | 0.28 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 53.07 | 34.16 |
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.